Clinical and MRI response to dose reduction of an etanercept-biosimilar for hip arthritis in patients with ankylosing spondylitis: an observational, retrospective cohort study

Huang, Zhixiang; Deng, Weiming; Guo, Xin; Huang, Zhengping; Huang, Yung-Cheng; Lin, Chun‐Cheng; Li, Tianwang

doi:10.1007/s10067-019-04466-9

Cited by 10 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We know from sacroiliitis that MRI has the potential of showing pathologies before obvious radiographic changes. Two studies are promising in showing that more than 70% of AS patients with clinical hip involvement showed MRI abnormalities ( 20 , 21 ). The changes they observed were joint effusion, bone marrow edema, and bone erosions.…”

Section: Discussionmentioning

confidence: 99%

A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features

et al. 2021

View full text Add to dashboard Cite

Ankylosing spondylitis (AS) is most common in adolescents and the ultimate result is disability, which places a huge burden on patients and society. Therefore, the key to improve the prognosis of AS is the early diagnosis of hip injury. To examine if AS patients whose hip pain is either absent or minimal might already have observable MRI and X-ray hip changes. Clinical and imaging hip data were systematically analyzed in 200 healthy controls (HC) and 300 AS with varying degrees of hip pain. Forty-four patients with early hip osteoarthritis (OA) served as positive imaging controls. In MRI images, BME lesions in the STIR sequence were much more frequent in AS (62%) compared to HC (2%) (p < 0.0001). Most importantly, 42% of AS with no or minimal hip pain had one or more MRI lesions. This was much more frequent compared to the 2% in HC (p < 0.05). These lesions in AS were observed singly or in combination in the trochanters (8%), femoral heads (12%), and acetabula (13%). Parallel finding that X-ray changes were present in patients with minimal or no hip pain was also observed with X-ray. Based on the normal hip width of HC, joint space narrowing was observed in 94.3% of the entire AS cohort, and importantly 56.7% of AS patients with no or mild hip pain. In these latter patients, functional activities of the hips such as walking were normal. At least 40% of AS patients with minimal or no hip pain might already show MRI and X-ray changes.

show abstract

Section: Discussionmentioning

confidence: 99%

A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In this study, we observed the treatment response from 12 weeks to 52 weeks. Lian et al and Huang et al [23]demonstrated that TNF-α inhibitor could maintain stable hip function by harris score and clinical remission of hip arthritis in SpA patients for 6 months. In this study, we simultaneously compared the effectiveness of TNF-α inhibitor and SSZ therapy on the clinical outcome of hip arthritis in SpA from baseline to 52 weeks.…”

Section: Discussionmentioning

confidence: 99%

“…More attentions turned to focus on the hip arthritis in SpA, and varies clinical studies including TNF-α inhibitor treatment or classical DMARDs treatment were conducted to observe the clinical and/or radiographic progress of hip joint and function. [23][24][25]. TNF-α inhibitor treatment had been demonstrated to be effect for SpA patients with hip involvement.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The clinical and MRI effect of TNF-α inhibitor in spondyloarthritis patients with hip involvement: a real-world prospective clinical study

Zhang

Zheng

Han

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Hip involvement is an important cause of disability and poor prognostic in patients with spondyloarthritis (SpA). TNF-α inhibitor treatment had been demonstrated to be effective in SpA patients with hip arthritis, however, quantitative assessment with magnetic resonance imaging (MRI) in the long-term follow-up still needs further application.Methods: A total of 239 patients were involved in this study, MTX and SSZ were given as basic treatment. 165 patients received TNF-α inhibitor plus basic treatment and 74 patients received basic treatment only as control. The clinical symptoms were assessed at baseline, week 12, week 24, and week 52. The MRI performances of hip arthritis including bone marrow edema (BME) and synovitis were quantitatively assessed using Hip MRI Inflammation Scoring System (HIMRISS).Results: The clinical symptoms of ESR, CRP, BASDAI, Harris, and ASDAS-ESR of both groups got significant clinical remission at week 52 (p<0.001). However, the disease activity change levels at week 52 in control group were significantly worse than TNF group. In week 52, MRI performance showed significant remission trend in TNF-α inhibitor group versus baseline of which total HIMRISS scores decreased significantly ( 26.49±10.37 vs 20.59±9.41, p<0.001), but the control group only had slight improvement trend (p<0.05).Conclusions: TNF-α inhibitor could significantly and better improve the clinical and MRI manifestation of hip involvement in SpA patients than controls. Quantitative MRI assessment combined with clinical assessment could accurately evaluate the treatment effect of TNF-α for SpA patients with hip involvement, and help to guide targeted treatment.Trial registration: Chinese Clinical Trial Registry, ChiCTR-ONRC-11001846, Registered 28 November 2011. Retrospectively registered http://www.chictr.org.cn/showproj.aspx?proj=7701

show abstract

“…The rhTNFR:Fc has been widely used in clinical practice in China for 14 years. Beside rheumatoid arthritis, active ankylosing spondylitis was also the indication of rhTNFR:Fc 13,14 . Comparing with MTX, rhTNFR:Fc revealed more disease activity improvement in Chinese rheumatoid arthritis patients 15 .…”

mentioning

confidence: 99%

Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study

Zhao

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Rheumatoid arthritis is a chronic inflammatory disease which could lead to severe joint damage and disability. This study was performed to determine the efficacy and safety of methotrexate (MTX) therapy combined with maintenance or discontinuation of etanercept biosimilar rhTNFR:Fc in active rheumatoid arthritis patients in Chinese patients. In this controlled, randomized and open-label study, 89 patients with active rheumatoid arthritis were enrolled at 7 institutions in China between September 2010 and May 2011. In a period of 52 weeks, patients were randomly assigned to one of three treatment groups: MTX plus rhTNFR:Fc for 52 weeks, MTX plus rhTNFR:Fc for 24 weeks, or MTX monotherapy. The primary endpoint was the joint damage evaluated by change from baseline (CFB) of van de Heijde modified Total Sharp Score (mTSS). Intention-to-treat population were used for analysis. A total of 89 enrolled patients were eligible for this study, of whom 32 were assigned to MTX plus rhTNFR:Fc52 group, 31 to MTX plus rhTNFR:Fc24, and 26 to MTX monotherapy. Only one patient was lost to follow up in the MTX plus rhTNFR:Fc24 group. The mTSS CFB was lower in the rhTNFR:Fc pooled group (combination of data in the MTX plus rhTNFR:Fc52 group and MTX plus rhTNFR:Fc24 group) comparing with MTX monotherapy at week 24 and 52 (P = 0.03 and P < 0.01). Additionally, ACR50 and ACR70 response rates were both higher in the rhTNFR:Fc pooled group than MTX monotherapy (P < 0.05). Combination of MTX and rhTNFR:Fc in patients with active rheumatoid arthritis could effectively inhibit joint structure damage.

show abstract

Clinical and MRI response to dose reduction of an etanercept-biosimilar for hip arthritis in patients with ankylosing spondylitis: an observational, retrospective cohort study

Cited by 10 publications

References 35 publications

A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features

A Comprehensive Assessment of Hip Damage in Ankylosing Spondylitis, Especially Early Features

The clinical and MRI effect of TNF-α inhibitor in spondyloarthritis patients with hip involvement: a real-world prospective clinical study

Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study

Contact Info

Product

Resources

About